Annual Cash & Cash Equivalents
$132.10 M
+$75.20 M+132.16%
01 December 2023
Summary:
Myriad Genetics annual cash & cash equivalents is currently $132.10 million, with the most recent change of +$75.20 million (+132.16%) on 01 December 2023. During the last 3 years, it has risen by +$15.10 million (+12.91%). MYGN annual cash & cash equivalents is now -48.68% below its all-time high of $257.40 million, reached on 31 December 2021.MYGN Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$99.90 M
+$7.50 M+8.12%
01 September 2024
Summary:
Myriad Genetics quarterly cash and cash equivalents is currently $99.90 million, with the most recent change of +$7.50 million (+8.12%) on 01 September 2024. Over the past year, it has dropped by -$32.20 million (-24.38%). MYGN quarterly cash and cash equivalents is now -66.16% below its all-time high of $295.20 million, reached on 30 September 2021.MYGN Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MYGN Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | -24.4% |
| 3 y3 years | +12.9% | -66.2% |
| 5 y5 years | +41.7% | +11.1% |
MYGN Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -48.7% | +132.2% | -66.2% | +86.4% |
| 5 y | 5 years | -48.7% | +132.2% | -66.2% | +86.4% |
| alltime | all time | -48.7% | +2346.3% | -66.2% | +1750.0% |
Myriad Genetics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $99.90 M(+8.1%) |
| June 2024 | - | $92.40 M(-4.6%) |
| Mar 2024 | - | $96.90 M(-26.6%) |
| Dec 2023 | $132.10 M(+132.2%) | $132.10 M(+73.8%) |
| Sept 2023 | - | $76.00 M(-26.1%) |
| June 2023 | - | $102.80 M(+91.8%) |
| Mar 2023 | - | $53.60 M(-5.8%) |
| Dec 2022 | $56.90 M(-77.9%) | $56.90 M(-48.6%) |
| Sept 2022 | - | $110.70 M(+5.2%) |
| June 2022 | - | $105.20 M(-36.3%) |
| Mar 2022 | - | $165.20 M(-35.8%) |
| Dec 2021 | $257.40 M(+120.0%) | $257.40 M(-12.8%) |
| Sept 2021 | - | $295.20 M(+149.3%) |
| June 2021 | - | $118.40 M(-20.5%) |
| Mar 2021 | - | $148.90 M(+25.9%) |
| Dec 2020 | $117.00 M(-28.5%) | - |
| Sept 2020 | - | $118.30 M(-27.7%) |
| June 2020 | $163.70 M(+75.6%) | $163.70 M(+35.3%) |
| Mar 2020 | - | $121.00 M(+49.0%) |
| Dec 2019 | - | $81.20 M(-9.7%) |
| Sept 2019 | - | $89.90 M(-3.5%) |
| June 2019 | $93.20 M(-16.0%) | $93.20 M(+9.8%) |
| Mar 2019 | - | $84.90 M(-6.3%) |
| Dec 2018 | - | $90.60 M(-2.9%) |
| Sept 2018 | - | $93.30 M(-15.9%) |
| June 2018 | $110.90 M(+8.3%) | $110.90 M(+13.9%) |
| Mar 2018 | - | $97.40 M(+9.8%) |
| Dec 2017 | - | $88.70 M(+0.9%) |
| Sept 2017 | - | $87.90 M(-14.2%) |
| June 2017 | $102.40 M(+49.5%) | $102.40 M(-17.3%) |
| Mar 2017 | - | $123.80 M(+14.5%) |
| Dec 2016 | - | $108.10 M(+24.4%) |
| Sept 2016 | - | $86.90 M(+26.9%) |
| June 2016 | $68.50 M(+6.9%) | $68.50 M(-43.2%) |
| Mar 2016 | - | $120.50 M(-10.5%) |
| Dec 2015 | - | $134.70 M(+54.1%) |
| Sept 2015 | - | $87.40 M(+36.3%) |
| June 2015 | $64.10 M(-1.1%) | $64.10 M(+16.1%) |
| Mar 2015 | - | $55.21 M(-7.5%) |
| Dec 2014 | - | $59.71 M(-14.5%) |
| Sept 2014 | - | $69.80 M(+7.7%) |
| June 2014 | $64.80 M(-37.7%) | $64.80 M(-24.5%) |
| Mar 2014 | - | $85.80 M(+19.8%) |
| Dec 2013 | - | $71.60 M(-15.8%) |
| Sept 2013 | - | $84.99 M(-18.3%) |
| June 2013 | $104.07 M(+20.5%) | $104.07 M(-7.3%) |
| Mar 2013 | - | $112.32 M(+64.2%) |
| Dec 2012 | - | $68.42 M(-28.4%) |
| Sept 2012 | - | $95.58 M(+10.7%) |
| June 2012 | $86.35 M(+63.9%) | $86.35 M(-17.6%) |
| Mar 2012 | - | $104.85 M(-3.7%) |
| Dec 2011 | - | $108.85 M(+73.7%) |
| Sept 2011 | - | $62.68 M(+19.0%) |
| June 2011 | $52.68 M(-43.3%) | $52.68 M(-21.8%) |
| Mar 2011 | - | $67.38 M(-0.4%) |
| Dec 2010 | - | $67.67 M(-45.1%) |
| Sept 2010 | - | $123.31 M(+32.8%) |
| June 2010 | $92.84 M | $92.84 M(-9.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2010 | - | $102.15 M(+69.0%) |
| Dec 2009 | - | $60.43 M(-33.7%) |
| Sept 2009 | - | $91.20 M(+43.6%) |
| June 2009 | $63.51 M(-73.3%) | $63.51 M(-68.4%) |
| Mar 2009 | - | $200.69 M(+12.1%) |
| Dec 2008 | - | $178.99 M(-22.3%) |
| Sept 2008 | - | $230.23 M(-3.2%) |
| June 2008 | $237.73 M(+65.7%) | $237.73 M(+67.0%) |
| Mar 2008 | - | $142.39 M(+24.3%) |
| Dec 2007 | - | $114.58 M(+6.9%) |
| Sept 2007 | - | $107.22 M(-25.2%) |
| June 2007 | $143.43 M(+45.5%) | $143.43 M(-26.4%) |
| Mar 2007 | - | $194.87 M(+126.9%) |
| Dec 2006 | - | $85.87 M(-3.1%) |
| Sept 2006 | - | $88.63 M(-10.1%) |
| June 2006 | $98.57 M(+99.1%) | $98.57 M(-7.4%) |
| Mar 2006 | - | $106.41 M(-10.3%) |
| Dec 2005 | - | $118.58 M(+206.2%) |
| Sept 2005 | - | $38.73 M(-21.8%) |
| June 2005 | $49.51 M(-41.0%) | $49.51 M(+2.3%) |
| Mar 2005 | - | $48.39 M(-22.6%) |
| Dec 2004 | - | $62.52 M(-4.5%) |
| Sept 2004 | - | $65.49 M(-22.0%) |
| June 2004 | $83.98 M(+36.3%) | $83.98 M(+79.0%) |
| Mar 2004 | - | $46.91 M(+10.5%) |
| Dec 2003 | - | $42.46 M(-12.0%) |
| Sept 2003 | - | $48.23 M(-21.7%) |
| June 2003 | $61.60 M(+0.9%) | $61.60 M(-23.4%) |
| Mar 2003 | - | $80.42 M(-17.1%) |
| Dec 2002 | - | $97.03 M(+100.0%) |
| Sept 2002 | - | $48.52 M(-20.5%) |
| June 2002 | $61.07 M(+69.9%) | $61.07 M(+4.3%) |
| Mar 2002 | - | $58.57 M(+10.1%) |
| Dec 2001 | - | $53.21 M(+12.3%) |
| Sept 2001 | - | $47.36 M(+31.8%) |
| June 2001 | $35.94 M(-36.1%) | $35.94 M(-62.6%) |
| Mar 2001 | - | $96.20 M(+4.1%) |
| Dec 2000 | - | $92.43 M(+57.6%) |
| Sept 2000 | - | $58.63 M(+4.3%) |
| June 2000 | $56.21 M(+941.0%) | $56.21 M(+95.3%) |
| Mar 2000 | - | $28.78 M(+3.9%) |
| Dec 1999 | - | $27.70 M(+76.4%) |
| Sept 1999 | - | $15.70 M(+190.7%) |
| June 1999 | $5.40 M(-63.0%) | $5.40 M(-34.9%) |
| Mar 1999 | - | $8.30 M(-52.0%) |
| Dec 1998 | - | $17.30 M(+88.0%) |
| Sept 1998 | - | $9.20 M(-37.0%) |
| June 1998 | $14.60 M(-7.0%) | $14.60 M(+9.0%) |
| Mar 1998 | - | $13.40 M(-21.2%) |
| Dec 1997 | - | $17.00 M(-16.7%) |
| Sept 1997 | - | $20.40 M(+29.9%) |
| June 1997 | $15.70 M(+18.9%) | $15.70 M(-6.0%) |
| Mar 1997 | - | $16.70 M(+9.2%) |
| Dec 1996 | - | $15.30 M(+3.4%) |
| Sept 1996 | - | $14.80 M(+12.1%) |
| June 1996 | $13.20 M | $13.20 M(-49.8%) |
| Mar 1996 | - | $26.30 M(-8.0%) |
| Dec 1995 | - | $28.60 M |
FAQ
- What is Myriad Genetics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Myriad Genetics?
- What is Myriad Genetics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Myriad Genetics?
- What is Myriad Genetics quarterly cash and cash equivalents year-on-year change?
What is Myriad Genetics annual cash & cash equivalents?
The current annual cash & cash equivalents of MYGN is $132.10 M
What is the all time high annual cash & cash equivalents for Myriad Genetics?
Myriad Genetics all-time high annual cash & cash equivalents is $257.40 M
What is Myriad Genetics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of MYGN is $99.90 M
What is the all time high quarterly cash and cash equivalents for Myriad Genetics?
Myriad Genetics all-time high quarterly cash and cash equivalents is $295.20 M
What is Myriad Genetics quarterly cash and cash equivalents year-on-year change?
Over the past year, MYGN quarterly cash and cash equivalents has changed by -$32.20 M (-24.38%)